Stock of the Day

Thermo Fisher Scientific (TMO)

$658.23

+$6.25 (+1.0%)

Market Cap: $243.30B

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally.

The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

Thermo Fisher Scientific Bull Case

Here are some ways that investors could benefit from investing in Thermo Fisher Scientific Inc.:

• Thermo Fisher Scientific Inc. recently reported strong third-quarter results, beating analyst expectations with earnings per share of $6.03 against a consensus of $5.71 and revenue of $11.99 billion, which exceeded the expected $11.71 billion, demonstrating robust operational performance and demand for its life sciences solutions.
• The company has raised its full-year 2026 earnings per share guidance to a range of $24.93 to $25.33, signaling management confidence in continued growth, while the stock currently trades at $660.97, reflecting a 52-week high of $694.33 and indicating strong market momentum and investor interest in its trajectory.
• Thermo Fisher Scientific Inc. is expanding its clinical research and drug development capabilities, recently signing a Study Start-Up Agreement with Quantum BioPharma to support a Phase 2 multiple sclerosis trial, which reinforces its role as a key partner in the biopharma sector and supports its Laboratory Products and Biopharma Services segment.
• Analyst sentiment remains positive with a consensus rating of Moderate Buy and an average price target of $633.13, while recent upgrades from firms like HSBC, which raised its rating to Strong Buy, and Deutsche Bank, which set a $720 price target, suggest that institutional investors see significant upside potential in the stock.
• The company maintains a solid financial position with a current ratio of 1.55 and a quick ratio of 1.18, indicating sufficient liquidity to cover short-term obligations, while its debt-to-equity ratio of 0.74 suggests a manageable leverage level that supports long-term stability and growth initiatives.

Thermo Fisher Scientific Bear Case

Investors should be bearish about investing in Thermo Fisher Scientific Inc. for these reasons:

• Thermo Fisher Scientific Inc. trades at a price-to-earnings ratio of 35.56, which is significantly higher than the broader market average, making the stock sensitive to any changes in growth expectations, interest rates, or market sentiment, as evidenced by a recent 4.2% drop that erased approximately $10 billion in market value in a single session.
• Insider selling has been notable in recent months, with CEO Marc N. Casper and other executives selling a combined 73,768 shares valued at $44,122,820 in the last ninety days, which may signal a lack of confidence from company leadership or a desire to diversify personal holdings at current price levels.
• The company faces macroeconomic uncertainty and foreign-exchange exposure, as noted by Zacks Research, which characterizes the outlook as balanced due to these risks, potentially impacting its international revenue streams and profitability in the North America, Europe, and Asia-Pacific regions.
• Short interest in Thermo Fisher Scientific Inc. has increased, with shares shorted rising to 5,019,933 as of September 15, 2026, representing a 1.36% short percentage of float, indicating that some investors are betting against the stock's future performance and potentially anticipating a decline in value.
• Some institutional investors have reduced their positions, such as S.E.E.D. Planning Group LLC, which cut its stake by 14.9% in the third quarter, and Citigroup, which lowered its rating from Buy to Underperform in September 2026, suggesting that certain market participants are taking profits or reassessing the stock's valuation relative to its growth prospects.

Recent News

• Thermo Fisher (TMO) Gets a Buy from Barclays (theglobeandmail.com)
• Thermo Fisher Scientific's Q3 2026 Earnings: What to Expect (barchart.com)
• What Could Thermo Fisher Scientific (TMO) Change With Its New Digital CMC Consortium? (finance.yahoo.com)
• Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight (finance.yahoo.com)
• Thermo Fisher Scientific Slides as Investors Appear to Take Profits Ahead of Earnings (quiverquant.com)
• Pharmaceutical CRO Market Forecasts Growth from $45.33B (2025) to $83.31B by 2033, Profiling IQVIA, ICON, Thermo Fisher, Medpace & 5 Other Key Players (finance.yahoo.com)
• PCR Market Report Forecasts qPCR, Digital PCR and Multiplex Testing Growth, Profiling 89 Companies Including Roche and Thermo Fisher (finance.yahoo.com)
• Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial (finance.yahoo.com)
• Thermo Fisher Scientific Inc. stock rises Monday, outperforms market (marketwatch.com)
• Cell-Based Assay & High Content Screening Market Report Reveals Why Technology Is Outpacing the Market, Profiling Thermo Fisher, Roche, Sartorius, Revvity & 50 Other Key Players (finance.yahoo.com)